(Q37588694)

21 August 2017

1 reference

title

Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases (English)

1 reference

21 August 2017

1 reference

Kjell S Sakariassen

1

1 reference

21 August 2017

Peteris Alberts

2

1 reference

21 August 2017

Pierre Fontana

3

1 reference

21 August 2017

Jessica Mann

4

1 reference

21 August 2017

Henri Bounameaux

5

1 reference

21 August 2017

Alexandra Santana Sorensen

6

1 reference

21 August 2017

language of work or name

1 reference

1 September 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

5

1 reference

21 August 2017

issue

5

1 reference

21 August 2017

page(s)

479-493

1 reference

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 August 2017

cites work

1 reference

New antiplatelet strategies in atherothrombosis and their indications

21 January 2018

1 reference

Insights into oxidative stress: the isoprostanes

21 January 2018

1 reference

The isoprostanes in biology and medicine

21 January 2018

1 reference

Aspirin as an antiplatelet drug

21 January 2018

1 reference

Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition--a magnetic resonance imaging study

21 January 2018

1 reference

Cell signalling through thromboxane A2 receptors

21 January 2018

1 reference

Mouse thromboxane A2 receptor: cDNA cloning, expression and northern blot analysis

21 January 2018

1 reference

Phosphorylation of the thromboxane receptor alpha, the predominant isoform expressed in human platelets.

21 January 2018

1 reference

The Thromboxane Receptor Antagonist PBT-3, a Hepoxilin Stable Analog, Selectively Antagonizes the TPα Isoform in Transfected COS-7 Cells

21 January 2018

1 reference

Role for thromboxane receptors in angiotensin-II-induced hypertension.

21 January 2018

1 reference

A role for the thromboxane receptor in L-NAME hypertension

21 January 2018

1 reference

From the design to the clinical application of thromboxane modulators

21 January 2018

1 reference

Prostanoid receptors: subtypes and signaling

21 January 2018

1 reference

Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2.

21 January 2018

1 reference

Oxidative stress and cardiovascular complications in diabetes: isoprostanes as new markers on an old paradigm.

21 January 2018

1 reference

Testosterone Increases Human Platelet Thromboxane A2 Receptor Density and Aggregation Responses

21 January 2018

1 reference

Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder

21 January 2018

1 reference

Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study

21 January 2018

1 reference

The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies.

21 January 2018

1 reference

Additions and Corrections to Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A(2) receptor

21 January 2018

1 reference

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

Thromboxane A2 receptor signaling inhibits vascular endothelial growth factor-induced endothelial cell differentiation and migration

21 January 2018

1 reference

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

21 January 2018

1 reference

Isoprostanes and the kidney

21 January 2018

1 reference

Prostaglandins in the kidney: developments since Y2K.

21 January 2018

1 reference

Nephrotic syndrome in adults

21 January 2018

1 reference

Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management

21 January 2018

1 reference

Increased platelet thromboxane synthesis in renal glomerular diseases

21 January 2018

1 reference

Thromboxane blockade reduces blood pressure and progression of renal failure independent of endothelin-1 in uremic rats

21 January 2018

1 reference

Antiproteinuric effect of a thromboxane receptor antagonist, S-1452, on rat diabetic nephropathy and murine lupus nephritis

21 January 2018

1 reference

The selective TP receptor antagonist, S18886 (terutroban), attenuates renal damage in the double transgenic rat model of hypertension

21 January 2018

1 reference

Thromboxane receptor blockade reduces renal injury in murine lupus nephritis

21 January 2018

1 reference

Role of ADP and thromboxanes in human thrombus formation in ex vivo models.

21 January 2018

1 reference

Update on oral antiplatelet therapy: principles, problems and promises

21 January 2018

1 reference

21 January 2018

1 reference

Platelet activation in type 2 diabetes mellitus

21 January 2018

1 reference

Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review

21 January 2018

1 reference

Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis.

21 January 2018

1 reference

Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents.

21 January 2018

1 reference

Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection

21 January 2018

1 reference

Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests

21 January 2018

1 reference

The continuous administration of aspirin attenuates atherosclerosis in apolipoprotein E-deficient mice.

21 January 2018

1 reference

Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis

21 January 2018

1 reference

Aspirin at low-intermediate concentrations protects retinal vessels in experimental diabetic retinopathy through non-platelet-mediated effects

21 January 2018

1 reference

Effects of clopidogrel and ticlopidine on experimental diabetic ischemic retinopathy in rats.

21 January 2018

1 reference

Effect of aspirin on prostanoids and nitric oxide production in streptozotocin-diabetic rats with ischemic retinopathy

21 January 2018

1 reference

Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway

21 January 2018

1 reference

Vascular endothelial cells synthesize nitric oxide from L-arginine

21 January 2018

1 reference

Carotid artery disease in NIDDM diabetes.

21 January 2018

1 reference

Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients

21 January 2018

1 reference

Thromboxane biosynthesis and platelet function in type II diabetes mellitus

21 January 2018

1 reference

Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease

21 January 2018

1 reference

Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study

21 January 2018

1 reference

The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension

21 January 2018

1 reference

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

21 January 2018

1 reference

Increased glomerular thromboxane synthesis as a possible cause of proteinuria in experimental nephrosis

21 January 2018

1 reference

Approaches to prevention of cardiovascular complications and events in diabetes mellitus

21 January 2018

1 reference

Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement

21 January 2018

1 reference

Aspirin for the Primary Prevention of Cardiovascular Events: An Update of the Evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

Antithrombotic agents in the prevention of ischemic stroke

21 January 2018

1 reference

Binding characteristics of the new thromboxane A2/prostaglandin H2 receptor antagonist [3H]BAY U 3405 to washed human platelets and platelet membranes

21 January 2018

1 reference

Ramatroban (BAY u 3405): a novel dual antagonist of TXA2 receptor and CRTh2, a newly identified prostaglandin D2 receptor

21 January 2018

1 reference

Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban.

21 January 2018

1 reference

Rationale and design of the Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study

21 January 2018

1 reference

The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease

21 January 2018

1 reference

Effects of Picotamide, an Antithromboxane Agent, on Carotid Atherosclerotic Evolution

21 January 2018

1 reference

Synthesis and structure of the platelet aggregation factor thromboxane A2

21 January 2018

1 reference

Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FCA.09.33

1 reference

21 August 2017

1 reference